LASN01
Based on 1 Customer Validation
LASN01 is a humanized antibody targeting IL-11R, with a Kd of 37 pM. LASN01 blocks the IL-11 signaling pathway via IL-11Rα, and inhibits the phosphorylation of STAT3 and ERK, as well as the expression of pro-inflammatory cytokines, hyaluronic acid, procollagen and fibrotic markers. LASN01 can be used in studies related to thyroid eye disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.96%
- Masse moléculaire:144.19 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
IL-11RA
LASN01 (0.001-100 nM; 1 h) inhibits IL-11-induced activation of pSTAT3 and pERK in DLD-1 cells, with IC50 values of 0.4 nM and 0.1 nM, respectively[1].
LASN01 (1-10 µg/mL; 1 h) inhibits the phosphorylation of STAT3, ERK and AKT induced by IL-11 as well as by IL-11+IGF-1 in orbital fibroblasts derived from TED patients[1].
LASN01 (0.003-10 µg/mL; 97 h) inhibits IL-11-induced hyaluronic acid (HA) release in orbital fibroblasts derived from patients with TED, with an IC50 of 50 ng/mL[1].
LASN01 (3 µg/mL; 97 h) inhibits the release of proinflammatory cytokines (including IL-6 and CCL2) induced by IL-11+IGF-1 in orbital fibroblasts derived from patients with TED[1].
LASN01 (3 µg/mL; 97 h) inhibits the release of type I procollagen in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy (TED) induced by TGFβ[1].
LASN01 (1-10 µg/mL; 6-48 h) modulates IL-11-induced and IL-11+IGF-1-induced gene expression in orbital fibroblasts derived from patients with thyroid-associated ophthalmopathy (TED), and specifically inhibits pathways related to inflammation, cytokine signaling and fibrosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLD-1 human colorectal adenocarcinoma cells
-
Concentration:0.001, 0.1, 1, 10 and 100 nM
-
Incubation Time:30 min (pre-incubation); 30 min (IL-11 stimulation)
-
Result:Potently inhibited IL-11-induced pSTAT3 activation with an IC50 of 0.4 nM.
Potently inhibited IL-11-induced pERK activation with an IC50 of 0.1 nM.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:3 µg/mL
-
Incubation Time:1 h (pre-incubation); 96 h (IL-11+IGF-1 stimulation)
-
Result:Significantly reduced HA release induced by the combination of IL-11 and IGF-1 to levels comparable to teprotumumab.
Further reduced HA release to near baseline levels when combined with teprotumumab.\nExhibited broad inhibition of multiple pro-inflammatory mediators.
Significantly reduced IL-6 and CCL2 release induced by IL-11 + IGF-1.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:3 µg/mL
-
Incubation Time:1 h (pre-incubation); 96 h (TGFβ stimulation)
-
Result:Significantly reduced TGFβ-induced procollagen I release from TED orbital fibroblasts.
-
Cell Line:thyroid eye disease (TED) patient-derived orbital fibroblasts
-
Concentration:1, 3 and 10 µg/mL
-
Incubation Time:48 h (qRT-PCR; co-incubated with IL-11+IGF-1); 6-48 h (RNAseq; co-incubated with IL-11 or IL-11+IGF-1)
-
Result:Downregulated 522 IL-11-induced genes at 6 hours and 95 IL-11-induced genes at 48 hours, including fibroinflammatory and extracellular matrix-related genes such as HAS2, C3, C4B, APLNR, and CHI3L1.
Downregulated 539 genes at 6 hours and 845 genes at 48 hours under IL-11+IGF-1 stimulation.
Reduced IL-11+IGF-1-induced expression of HAS2, IL-6, and CCL2 mRNA as confirmed by qRT-PCR.
Primarily inhibited pathways linked to inflammation, cytokine signaling, glycosaminoglycan production, and fibrosis as shown by gene ontology analysis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 144.19 kDa
-
Color Colorless to light yellow
-
SMILES
[LASN01]
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LASN01 Related Classifications
HY-P991487 Related Classifications
Powered by Bioz